Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Synovitis, Pigmented Villonodular 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Pancreatic Cancer 1Advanced Malignancies 1Advanced Cancer 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × cabiralizumab × Clear all
NCT03336216 2024-07-23

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Bristol-Myers Squibb

Phase 2 Completed
205 enrolled 30 charts
Gastrointestinal

Advanced Pancreatic Cancer

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT02526017 2022-03-09

FPA008-003

Five Prime Therapeutics, Inc.

Phase 1 Completed
313 enrolled 30 charts
CNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioma, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02471716 2021-08-31

FPA008-002

Five Prime Therapeutics, Inc.

Phase 1/2 Completed
66 enrolled 20 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT03158272 2020-12-21

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Bristol-Myers Squibb

Phase 1 Completed
19 enrolled 26 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡